Read Gene

Read Gene Accounts Payable

The Accounts Payable of Read Gene (RDG.WA) as of Nov 6, 2026 is 1.57 M PLN. In the previous year, Accounts Payable was 1.44 M PLN — a change of 8.92% (higher).

Accounts Payable

1.57 MPLN

YoY

8.92%

Last updated:

Accounts Payable of Read Gene is 2025 1.57 M PLN. Accounts Payable of Read Gene was 2024 1.44 M PLN. It decreases by 8.92% higher compared to the previous year.

The Read Gene Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2014
289,100.00 PLN
Jan 1, 2020
562,996.80 PLN
Jan 1, 2021
787,697.40 PLN
Jan 1, 2022
617,464.00 PLN
Jan 1, 2023
1.06 M PLN
Jan 1, 2024
1.44 M PLN
Jan 1, 2025
1.57 M PLN
The Read Gene Accounts Payable history
YEARAccounts PayableYoY
1.57 MPLN+8.92%
1.44 MPLN+35.92%
1.06 MPLN+71.70%
617,464.00PLN-21.61%
787,697.40PLN+39.91%
562,996.80PLN+94.74%
289,100.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Accounts Payable of Read Gene is 1.57 M PLN in 2025.

Accounts Payable of Read Gene changed from 1.44 M PLN to 1.57 M PLN, representing a 8.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Read Gene since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Read Gene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Read Gene